Entwisle C, et al. - Safety and immunogenicity of a novel vaccine candidate PnuBioVax was tested in healthy young adults. Findings demonstrated that all dose levels were considered safe and well tolerated. Data also showed that compared to 50 µg and placebo, statistically significant increase in anti-PnuBioVax IgG titres was seen at the 200 and 500 µg dose levels.